Cargando…
Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management
Type 2 diabetes mellitus (T2DM) is a global pandemic, as evident from the global cartographic picture of diabetes by the International Diabetes Federation (http://www.diabetesatlas.org/). Diabetes mellitus is a chronic, progressive, incompletely understood metabolic condition chiefly characterized b...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256065/ https://www.ncbi.nlm.nih.gov/pubmed/28167928 http://dx.doi.org/10.3389/fendo.2017.00006 |
_version_ | 1782498643090079744 |
---|---|
author | Chaudhury, Arun Duvoor, Chitharanjan Reddy Dendi, Vijaya Sena Kraleti, Shashank Chada, Aditya Ravilla, Rahul Marco, Asween Shekhawat, Nawal Singh Montales, Maria Theresa Kuriakose, Kevin Sasapu, Appalanaidu Beebe, Alexandria Patil, Naveen Musham, Chaitanya K. Lohani, Govinda Prasad Mirza, Wasique |
author_facet | Chaudhury, Arun Duvoor, Chitharanjan Reddy Dendi, Vijaya Sena Kraleti, Shashank Chada, Aditya Ravilla, Rahul Marco, Asween Shekhawat, Nawal Singh Montales, Maria Theresa Kuriakose, Kevin Sasapu, Appalanaidu Beebe, Alexandria Patil, Naveen Musham, Chaitanya K. Lohani, Govinda Prasad Mirza, Wasique |
author_sort | Chaudhury, Arun |
collection | PubMed |
description | Type 2 diabetes mellitus (T2DM) is a global pandemic, as evident from the global cartographic picture of diabetes by the International Diabetes Federation (http://www.diabetesatlas.org/). Diabetes mellitus is a chronic, progressive, incompletely understood metabolic condition chiefly characterized by hyperglycemia. Impaired insulin secretion, resistance to tissue actions of insulin, or a combination of both are thought to be the commonest reasons contributing to the pathophysiology of T2DM, a spectrum of disease originally arising from tissue insulin resistance and gradually progressing to a state characterized by complete loss of secretory activity of the beta cells of the pancreas. T2DM is a major contributor to the very large rise in the rate of non-communicable diseases affecting developed as well as developing nations. In this mini review, we endeavor to outline the current management principles, including the spectrum of medications that are currently used for pharmacologic management, for lowering the elevated blood glucose in T2DM. |
format | Online Article Text |
id | pubmed-5256065 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-52560652017-02-06 Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management Chaudhury, Arun Duvoor, Chitharanjan Reddy Dendi, Vijaya Sena Kraleti, Shashank Chada, Aditya Ravilla, Rahul Marco, Asween Shekhawat, Nawal Singh Montales, Maria Theresa Kuriakose, Kevin Sasapu, Appalanaidu Beebe, Alexandria Patil, Naveen Musham, Chaitanya K. Lohani, Govinda Prasad Mirza, Wasique Front Endocrinol (Lausanne) Endocrinology Type 2 diabetes mellitus (T2DM) is a global pandemic, as evident from the global cartographic picture of diabetes by the International Diabetes Federation (http://www.diabetesatlas.org/). Diabetes mellitus is a chronic, progressive, incompletely understood metabolic condition chiefly characterized by hyperglycemia. Impaired insulin secretion, resistance to tissue actions of insulin, or a combination of both are thought to be the commonest reasons contributing to the pathophysiology of T2DM, a spectrum of disease originally arising from tissue insulin resistance and gradually progressing to a state characterized by complete loss of secretory activity of the beta cells of the pancreas. T2DM is a major contributor to the very large rise in the rate of non-communicable diseases affecting developed as well as developing nations. In this mini review, we endeavor to outline the current management principles, including the spectrum of medications that are currently used for pharmacologic management, for lowering the elevated blood glucose in T2DM. Frontiers Media S.A. 2017-01-24 /pmc/articles/PMC5256065/ /pubmed/28167928 http://dx.doi.org/10.3389/fendo.2017.00006 Text en Copyright © 2017 Chaudhury, Duvoor, Reddy Dendi, Kraleti, Chada, Ravilla, Marco, Shekhawat, Montales, Kuriakose, Sasapu, Beebe, Patil, Musham, Lohani and Mirza. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Chaudhury, Arun Duvoor, Chitharanjan Reddy Dendi, Vijaya Sena Kraleti, Shashank Chada, Aditya Ravilla, Rahul Marco, Asween Shekhawat, Nawal Singh Montales, Maria Theresa Kuriakose, Kevin Sasapu, Appalanaidu Beebe, Alexandria Patil, Naveen Musham, Chaitanya K. Lohani, Govinda Prasad Mirza, Wasique Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management |
title | Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management |
title_full | Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management |
title_fullStr | Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management |
title_full_unstemmed | Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management |
title_short | Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management |
title_sort | clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256065/ https://www.ncbi.nlm.nih.gov/pubmed/28167928 http://dx.doi.org/10.3389/fendo.2017.00006 |
work_keys_str_mv | AT chaudhuryarun clinicalreviewofantidiabeticdrugsimplicationsfortype2diabetesmellitusmanagement AT duvoorchitharanjan clinicalreviewofantidiabeticdrugsimplicationsfortype2diabetesmellitusmanagement AT reddydendivijayasena clinicalreviewofantidiabeticdrugsimplicationsfortype2diabetesmellitusmanagement AT kraletishashank clinicalreviewofantidiabeticdrugsimplicationsfortype2diabetesmellitusmanagement AT chadaaditya clinicalreviewofantidiabeticdrugsimplicationsfortype2diabetesmellitusmanagement AT ravillarahul clinicalreviewofantidiabeticdrugsimplicationsfortype2diabetesmellitusmanagement AT marcoasween clinicalreviewofantidiabeticdrugsimplicationsfortype2diabetesmellitusmanagement AT shekhawatnawalsingh clinicalreviewofantidiabeticdrugsimplicationsfortype2diabetesmellitusmanagement AT montalesmariatheresa clinicalreviewofantidiabeticdrugsimplicationsfortype2diabetesmellitusmanagement AT kuriakosekevin clinicalreviewofantidiabeticdrugsimplicationsfortype2diabetesmellitusmanagement AT sasapuappalanaidu clinicalreviewofantidiabeticdrugsimplicationsfortype2diabetesmellitusmanagement AT beebealexandria clinicalreviewofantidiabeticdrugsimplicationsfortype2diabetesmellitusmanagement AT patilnaveen clinicalreviewofantidiabeticdrugsimplicationsfortype2diabetesmellitusmanagement AT mushamchaitanyak clinicalreviewofantidiabeticdrugsimplicationsfortype2diabetesmellitusmanagement AT lohanigovindaprasad clinicalreviewofantidiabeticdrugsimplicationsfortype2diabetesmellitusmanagement AT mirzawasique clinicalreviewofantidiabeticdrugsimplicationsfortype2diabetesmellitusmanagement |